Calviri

Executive Summary

Calviri is a Phoenix-based biotechnology company founded in 2017 with a mission to end cancer in both dogs and humans. The company focuses on multi-cancer diagnostic tests designed to detect cancer at its earliest, most treatable stage (Stage 1) and develops therapeutic and preventative vaccines targeting shared tumor antigens. Calviri's strategy involves first commercializing its products in the veterinary oncology market, leveraging the faster regulatory pathway and lower costs, before advancing similar technologies for human cancers. This dual-species approach allows the company to generate early revenue and clinical data while de-risking its human programs. The company's diagnostic platform aims to address the critical need for early cancer detection, potentially improving survival rates significantly. By focusing on shared antigens, their vaccine candidates could offer broad protection across multiple cancer types. Calviri's model is capital-efficient, using veterinary sales to fund human development, and positions the company at the intersection of animal health and human oncology, a niche with growing investor interest.

Upcoming Catalysts (preview)

• Q4 2026Completion of canine multi-cancer diagnostic validation study75% success
• 2026Partnership announcement for veterinary vaccine commercialization60% success
• TBDFirst-in-human clinical trial initiation for lead vaccine candidate40% success